We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
CLAIRE
GLEMAS
claire.glemas@nhs.net
Dr
Matthias
Zilbauer
mz304@medschl.cam.ac.uk
Dr
Matthias
Zilbauer
mz304@medschl.cam.ac.uk
Diseases of oesophagus, stomach and duodenum
This information is provided directly by researchers and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information.
The human intestinal mucosa represents the largest body surface, which is constantly exposed to a complex microbial community. A finely tuned homeostasis develops between host cells including the intestinal epithelium, associated mucosal immune cells and the environment. There is increasing evidence to suggest that exposure to environmental factors at critical time periods such as in utero or post-partum may have a significant effect on the development of this physiological intestinal homeostasis.
Alterations to these physiological processes have been associated with the development of gastrointestinal (GI) disease, such as necrotising enterocolitis (NEC) and inflammatory bowel diseases (IBD). Moreover, increasing evidence suggests that the digestive tract may also play a critical role in the development of other multi-factorial diseases.
Major aspects of some of the fundamental processes involved in human intestinal physiology and pathology remain unknown, and one of the main reasons for this is the availability of data derived from human tissue. In order to further our understanding of molecular mechanisms in health and disease to improve human health there is a need for carefully designed translational research studies.
The overall aim of this study is to further our understanding of human intestinal health and disease through the use of prospectively obtained human tissue samples in conjunction with corresponding detailed clinical data.
The key themes for the study include:
- Investigating the role of epigenetics in the intestinal mucosa and its implication in regulating cellular function during GI health and disease.
- Development of clinically applicable diagnsotic and prognostic biomarkers in paediatric inflammatory bowel disease
- Development and use of human intestinal organoid culture models as translational research tools to investigate GI physiology and pathology
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Cohort study;
You can take part if:
You may not be able to take part if:
Based on the various aspects and large scope of our study any sample obtained will be of major importance and relevance. Hence, there are no specific exclusion criteria.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
CLAIRE
GLEMAS
claire.glemas@nhs.net
Dr
Matthias
Zilbauer
mz304@medschl.cam.ac.uk
Dr
Matthias
Zilbauer
mz304@medschl.cam.ac.uk
The study is sponsored by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST and funded by ACTION MEDICAL RESEARCH .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 34481
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
